- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
isturisa
Synonyms :
osilodrostat
Class :
Adrenal corticosteroid inhibitors
Dosage Forms & Strengths
Tablet
1mg
5mg
10mg
Initial dose
:
2
mg
Orally
twice a day
Tablet
Titration:1 to 2mg twice a day initially, no more than two weeks
Maintenance dose:2-7mg twice a day
maximum dose-30mg
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
QTc interval is increased both by lenvatinib and osilodrosta
CYP3A strong enhancers of the small intestine may reduce the bioavailability of osilodrostat
OATP1B1/1B3 inhibitors increase the concentration of elagolix in the serum
OATP1B1/1B3 inhibitors increase the concentration of elbasvir and grazoprevir in the serum
OATP1B1/1B3 inhibitors increase the concentration of voxilaprevir in the serum
it increases the concentration of OATP1B1/1B3 substrates in the serum
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
the effect of osilodrostat is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
may increase the levels serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) substrates
OATP1B1/1B3 inhibitors increase the concentration of brincidofovir in the serum
OATP1B1/1B3 inhibitors increase the concentration of eluxadoline in the serum
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
Frequency defined:
>10%
Fatigue
Headache
Nasopharyngitis
Arthralgia
Rash
Blood corticotrophin increased
Abdominal pain
Myalgia
Abnormal hormone level
Urinary tract infection
Pyrexia
Cough
Influenza
Adrenal insufficiency
Nausea
Edema
Vomiting
Back pain
Diarrhea
Dizziness
Hypokalemia
Decreased appetite
Hypotension
Anemia
Hypertension
1-10%
Acne
Insomnia
Depression
Malaise
Alopecia
ECG QT prolongation
Hirsutism
Dyspepsia
Anxiety
Gastroenteritis
Tachycardia
Increased transaminases
Syncope
Pregnancy consideration: D
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient information leaflet
Generic Name: osilodrostat
Pronounced: [ O-sil-OH-droe-stat]
Why do we use osilodrostat?
It is used to treat Cushing’s disease
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
